Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BIOX
stocks logo

BIOX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q3
FY2026Q4
107.00M
+0.19%
0.075
+4587.5%
60.27M
-0.55%
-0.085
+310.63%
81.73M
+9.86%
-0.160
-77.17%
Estimates Revision
The market is revising Downward the revenue expectations for Bioceres Crop Solutions Corp. (BIOX) for FY2026, with the revenue forecasts being adjusted by -8.67% over the past three months. During the same period, the stock price has changed by -41.70%.
Revenue Estimates for FY2026
Revise Downward
down Image
-8.67%
In Past 3 Month
EPS Estimates for FY2026
Revise Upward
up Image
+26.09%
In Past 3 Month
Stock Price
Go Down
down Image
-41.70%
In Past 3 Month
Wall Street analysts forecast BIOX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIOX is 11.08 USD with a low forecast of 2.25 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast BIOX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIOX is 11.08 USD with a low forecast of 2.25 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
3 Hold
0 Sell
Hold
Current: 1.580
sliders
Low
2.25
Averages
11.08
High
26.00
Current: 1.580
sliders
Low
2.25
Averages
11.08
High
26.00
Canaccord
Hold
downgrade
2025-11-14
Reason
Canaccord
Price Target
2025-11-14
downgrade
Hold
Reason
Canaccord lowered the firm's price target on Bioceres to $2.25 from $2.50 and keeps a Hold rating on the shares. The firm reported lower Q1 revenues and adjusted EBITDA. The company has executed well on management's previously stated business priorities, including efforts to improve the business's margin profile, reduce operating expenses and better manage WC. Management cited expectations for the sustained unwinding of the seed business to temporarily lower upfront revenue recognition for the next two quarters in the segment.
Oppenheimer
Oppenheimer
Outperform -> Perform
downgrade
2025-10-22
Reason
Oppenheimer
Oppenheimer
Price Target
2025-10-22
downgrade
Outperform -> Perform
Reason
Oppenheimer downgraded Bioceres to Perform from Outperform without a price target. The firm believes the company's portfolio recapitalization "now appears incrementally challenging." Bioceres is seeing pressure amid Argentina liquidity concerns, and the notice of default from one its largest stakeholders "creates a significant impediment to our portfolio transformation thesis," the analyst tells investors in a research note. Oppenheimer cites Argentina volatility for the downgrade.
Canaccord
Buy
to
Hold
downgrade
2025-09-10
Reason
Canaccord
Price Target
2025-09-10
downgrade
Buy
to
Hold
Reason
Canaccord downgraded Bioceres to Hold from Buy with a price target of $2.50, down from $6.50. The company's sales and adjusted EBITDA loss in fiscal Q4 were lower than expected due to macro challenges being faced by agriculture customers in in its core market of Argentina, the analyst tells investors in a research note. The firm cites the challenging market in Argentina and the overhang of Bioceres' parent company reducing its position for the downgrade.
Lake Street
Ben Klieve
Buy
downgrade
$8 -> $5
2025-09-10
Reason
Lake Street
Ben Klieve
Price Target
$8 -> $5
2025-09-10
downgrade
Buy
Reason
Lake Street analyst Ben Klieve lowered the firm's price target on Bioceres to $5 from $8 and keeps a Buy rating on the shares. Q4 results were materially below all estimates in each segment, though the firm believes FY25 will prove to be an EBITDA trough and sees value in the next-generation products throughout Bioceres' portfolio, the analyst tells investors in a post-earnings note.
Brookline
Buy
to
Hold
downgrade
$26
2025-08-22
Reason
Brookline
Price Target
$26
2025-08-22
downgrade
Buy
to
Hold
Reason
Brookline downgraded Bioceres to Hold from Buy with a $26 price target. The firm views the timing of the CFO's departure as concerning.
Oppenheimer
Outperform
to
NULL
downgrade
$7 -> $6
2025-07-15
Reason
Oppenheimer
Price Target
$7 -> $6
2025-07-15
downgrade
Outperform
to
NULL
Reason
Oppenheimer lowered the firm's price target on Bioceres to $6 from $7 and keeps an Outperform rating on the shares. Coming into Q2 results, the firm notes a shift in investor sentiment, with the key debate in the agriculture space whether the reversion trade has run its course. Mixed with seasonal commodity weakness, Oppenheimer sees this now divided sentiment providing a difficult set-up into Q2 earnings season. The firm believes inputs have the opportunity to surprise to the upside, even against elevated expectations.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Bioceres Crop Solutions Corp (BIOX.O) is 0.00, compared to its 5-year average forward P/E of 23.77. For a more detailed relative valuation and DCF analysis to assess Bioceres Crop Solutions Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
23.77
Current PE
0.00
Overvalued PE
37.25
Undervalued PE
10.30

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
10.08
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
12.13
Undervalued EV/EBITDA
8.02

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.45
Current PS
0.00
Overvalued PS
2.00
Undervalued PS
0.89
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

BIOX News & Events

Events Timeline

(ET)
2025-09-23
07:05:26
Bioceres and Colorado Wheat Research Foundation Collaborate on HB4 Wheat Commercialization
select
2025-09-09 (ET)
2025-09-09
06:03:26
Bioceres announces Q4 revenue of $74.7M, falling short of consensus estimate of $110.08M
select
2025-08-22 (ET)
2025-08-22
07:41:24
Bioceres CFO Lopez Lecube Resigns
select
link
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-15Benzinga
Canaccord Genuity Keeps Hold Rating on Bioceres Crop Solutions, Reduces Price Target to $2.25

  • Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts to stay updated on market movements.

  • Exclusive Stories: The platform provides unique stories generated by Benzinga reporters, enhancing trading insights.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing valuable market intelligence.

  • Market Winning Tool: Benzinga Pro is designed to help traders succeed in the markets by providing accurate and timely information.

[object Object]
Preview
9.5
11-13NASDAQ.COM
Bioceres Crop (BIOX) Posts Q1 Loss and Falls Short of Revenue Projections

  • Quarterly Performance: Bioceres Crop (BIOX) reported a quarterly loss of $0.12 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.04, and revenues of $77.3 million, missing estimates by 18.37%.

  • Stock Outlook: The company's shares have declined by 68.3% this year, contrasting with the S&P 500's 16.4% gain, but current favorable earnings estimate revisions have resulted in a Zacks Rank #2 (Buy) for the stock.

  • Industry Context: Bioceres operates in the Agriculture - Operations industry, which is currently ranked in the bottom 20% of Zacks industries, indicating potential challenges ahead for stock performance.

  • Upcoming Reports: Another industry player, Cibus (CBUS), is set to report its quarterly results on November 13, with expectations of a significant loss and declining revenues compared to the previous year.

[object Object]
Preview
9.5
11-13Yahoo Finance
Bioceres Crop Solutions Announces Financial and Operational Results for Fiscal Q1 2026

  • Financial Performance: Bioceres Crop Solutions reported total revenues of $77.5 million in 1Q26, a 17% decline year-over-year, with a net loss of $7.5 million and an Adjusted EBITDA of $13.6 million, reflecting a 61% increase from the previous year.

  • Operational Improvements: Despite lower revenues, the company achieved a gross profit of $36.2 million, with gross margin expanding to 47% due to a more profitable product mix and reduced operating expenses.

  • Management Insights: CEO Federico Trucco highlighted progress in improving revenue quality, protecting margins, and maintaining cost discipline, while acknowledging ongoing challenges in the Argentine market.

  • Strategic Focus: Bioceres is prioritizing actions to strengthen its capital structure and enhance financial flexibility, aiming for long-term resilience through improved margin quality and working-capital efficiency.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Bioceres Crop Solutions Corp (BIOX) stock price today?

The current price of BIOX is 1.58 USD — it has decreased -0.63 % in the last trading day.

arrow icon

What is Bioceres Crop Solutions Corp (BIOX)'s business?

Bioceres Crop Solutions Corp. is a provider of crop productivity technologies designed to enable the transition of agriculture towards carbon neutrality. Its segments include Seed and integrated products, Crop protection and Crop nutrition. Seed and integrated products segment focuses on the development and commercialization of seed technologies and products, including provision of seed technologies integrated with crop protection and crop nutrition products designed to control weeds, insects or diseases, to increase their quality characteristics. Crop protection segment includes the development, production and marketing of adjuvants and a range of pest control molecules and biocontrol products. Crop nutrition segment focuses on the development, production and commercialization of inoculants that allow the biological fixation of nitrogen in the crops, and of fertilizers, including biofertilizers and micro-granulated fertilizers that optimize the productivity and yield of the crops.

arrow icon

What is the price predicton of BIOX Stock?

Wall Street analysts forecast BIOX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIOX is 11.08 USD with a low forecast of 2.25 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Bioceres Crop Solutions Corp (BIOX)'s revenue for the last quarter?

Bioceres Crop Solutions Corp revenue for the last quarter amounts to 77.44M USD, decreased -16.39 % YoY.

arrow icon

What is Bioceres Crop Solutions Corp (BIOX)'s earnings per share (EPS) for the last quarter?

Bioceres Crop Solutions Corp. EPS for the last quarter amounts to -0.12 USD, increased 20.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Bioceres Crop Solutions Corp (BIOX)'s fundamentals?

The market is revising Downward the revenue expectations for Bioceres Crop Solutions Corp. (BIOX) for FY2026, with the revenue forecasts being adjusted by -8.67% over the past three months. During the same period, the stock price has changed by -41.70%.
arrow icon

How many employees does Bioceres Crop Solutions Corp (BIOX). have?

Bioceres Crop Solutions Corp (BIOX) has 751 emplpoyees as of December 05 2025.

arrow icon

What is Bioceres Crop Solutions Corp (BIOX) market cap?

Today BIOX has the market capitalization of 100.30M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free